World's Best Scientists 2026 revealed!
Eric Van Cutsem

Eric Van Cutsem

Award Badge
Best Scientists
2025
Award Badge
Medicine
Belgium
2026

D-Index & Metrics

Best Scientists

D-Index
186
Citations
190330
World Ranking
479
National Ranking
3

Medicine

D-Index
192
Citations
204174
World Ranking
238
National Ranking
3

Research.com Recognitions

  • 2026 - Research.com Medicine in Belgium Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in Belgium Leader Award
  • 2023 - Research.com Medicine in Belgium Leader Award
  • 2022 - Research.com Medicine in Belgium Leader Award

Overview

Eric Van Cutsem is affiliated with KU Leuven in Belgium and has a research focus rooted in medicine, particularly oncology. Their body of work spans over 1,000 publications, with significant contributions to oncology, pulmonary and respiratory medicine, surgery, pathology and forensic medicine, and cancer research.

Their research emphasizes several main topics, including colorectal cancer treatments and studies, gastric cancer management and outcomes, cancer immunotherapy and biomarkers, pancreatic and hepatic oncology research, esophageal cancer research and treatment, genetic factors in colorectal cancer, and cancer genomics and diagnostics.

Eric Van Cutsem has published extensively in prominent scientific journals. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • New England Journal of Medicine
  • European Journal of Cancer

Their recent notable papers demonstrate engagement with clinical oncology and cancer immunotherapy topics. These papers include:

  • "Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer," 2020, New England Journal of Medicine
  • "Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer," 2021, New England Journal of Medicine
  • "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study," 2020, The Lancet Oncology
  • "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer," 2020, JAMA Oncology
  • "The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer," 2021, Nature

The scientist frequently collaborates with several researchers in their field, with the top co-authors being:

  • Josep Tabernero
  • Takayuki Yoshino
  • Kohei Shitara
  • Thierry André
  • Sara Lonardi

Eric Van Cutsem's work covers a wide range of clinical and translational research within oncology, combining studies on immunotherapy, genetic factors, and treatment outcomes in various gastrointestinal cancers.

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

    Eric Van Cutsem;Claus Henning Köhne;Erika Hitre;Jerzy Zaluski

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    James C. Yao;Manisha H. Shah;Tetsuhide Ito;Catherine Lombard Bohas

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

    Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

    Eric Van Cutsem;Vladimir M. Moiseyenko;Sergei Tjulandin;Alejandro Majlis

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

    Thierry André;Kai-Keen Shiu;Tae Won Kim;Benny Vittrup Jensen

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Sabine Tejpar
Sabine Tejpar KU Leuven
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Marc Peeters
Marc Peeters University of Antwerp
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Thierry André
Thierry André Université Paris Cité
Alfredo Falcone
Alfredo Falcone University of Pisa
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a career in medicine, a range of related online degrees can broaden your opportunities within healthcare. For those interested in managing healthcare facilities or leading teams, online healthcare administration programs offer flexibility and industry-focused training.

Earning a master’s degree is a common path for career advancement. You can explore some of the cheapest online mha programs to obtain advanced credentials at a more affordable cost.

For nurses seeking to reach the highest clinical levels, Doctor of Nursing Practice (DNP) programs are increasingly available online. Take a look at the cheapest dnp options to advance your nursing career without leaving your current job.

Aspiring pharmacists can also benefit from distance learning. Programs such as pharmacy school online accredited allow you to earn your degree with greater convenience while ensuring proper accreditation.

Choosing the right online degree can open doors to leadership, research, or advanced practice roles in healthcare—providing flexibility and cost savings along the way.

Best Scientists Citing Eric Van Cutsem

Trending Scientists

Recently Published Articles